Interactions of CD147 Involved in MMP Induction

CD147 参与 MMP 诱导的相互作用

• 批准号: 6875392
• 负责人: MARTIN E HEMLER
• 金额: $ 27.61万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-30 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6875392
• 关键词: binding sites; carcinogenesis; cell line; collagenase; gene induction /repression; human tissue; integrins; intermolecular interaction; laboratory mouse; membrane proteins; metalloendopeptidases; neoplasm /cancer invasiveness; neoplastic cell; neoplastic growth; oncoproteins; protein protein interaction; protein structure function; receptor binding

DESCRIPTION (provided by applicant): The cell surface IgSF protein CD147/EMMPRIN/basigin, binds to peritumor stromal cells or to other tumor cells, leading to MMP production, extracellular matrix degradation, and elevated tumor invasion and metastasis. Despite the growing CD 147 literature (300 papers in Medline), relevant counter-receptors remain to be identified, and mechanisms for MMP induction and tumor regulatory functions need to be established. We now define six molecular targets likely to be important for CD 147 function. These targets include novel CD 147 counter-receptor molecules, the homophilic ligand binding site (within the first Ig domain of CD 147), integrin association site (first Ig domain), the site required for caveolin-1 association (second Ig domain), a potential transmembrane domain interaction site, and a cytoplasmic domain site involved in MMP "induction. We propose to rigorously test the importance of each of these target sites for coordinated associations with other proteins, for MMP production in vitro, and for tumorigenicity in vivo. First, we will identify and characterize the CD 147 counter-receptors utilized during MMP-1 and MMP-2 induction. Second, we will determine CD 147 domain 1 sites required for counter-receptor binding and association with o3j81 integrin, and then we will evaluate the role of these sites during MMP-1 and MMP-2 production. Third, we will utilize domain 2 mutants to test the hypothesis that CD147-caveolin-l complexes suppress MMP induction by preventing CD 147 glycosylation and multimerization. Fourth, we will investigate the role of a highly conserved transmembrane glutamic residue (E218) with respect to protein-protein associations (including monocarboxylate transporter association), and CD147 MMP-inducing functions. Fifth, the CD147 cytoplasmic tail will be used as a probe to search for associated intracellular molecules critical for CD147 functions. Sixth, key mutants defined and characterized in Aims 2-5 will be expressed in breast cancer cell lines and tested for effects on tumor cells in vitro and in orthotopic mouse models in vivo. Our new insights into the coordination of counter-receptor binding, MMP induction, cell adhesion, lactate utilization, and caveolin/microdomain organization should provide an integrated framework in which to better understand the dramatic effects of CD 147 on the invasive behavior of tumor cells.

描述（由申请人提供）：细胞表面IgSF蛋白CD147/EMMPRIN/basigin与肿瘤周围基质细胞或其他肿瘤细胞结合，导致MMP产生，细胞外基质降解，肿瘤侵袭和转移升高。尽管有越来越多的cd147文献（Medline上有300篇论文），但相关的对抗受体仍有待鉴定，MMP诱导和肿瘤调节功能的机制需要建立。我们现在确定了六个可能对cd147功能很重要的分子靶点。这些靶点包括新的cd147反受体分子、亲同型配体结合位点（在cd147的第一个Ig结构域内）、整合素结合位点（第一个Ig结构域）、小窝蛋白-1结合所需的位点（第二个Ig结构域）、潜在的跨膜结构域相互作用位点以及参与MMP诱导的细胞质结构域位点。我们建议严格测试这些靶位点在与其他蛋白质协调结合、体外MMP生产和体内致瘤性方面的重要性。首先，我们将鉴定和表征MMP-1和MMP-2诱导过程中使用的cd147对抗受体。其次，我们将确定对抗受体结合和与o3j81整合素结合所需的cd147结构域1位点，然后我们将评估这些位点在MMP-1和MMP-2产生过程中的作用。第三，我们将利用结构域2突变体来验证cd147 -caveolin- 1复合物通过阻止cd147糖基化和多聚来抑制MMP诱导的假设。第四，我们将研究高度保守的跨膜谷氨酸残基（E218）在蛋白质-蛋白质关联（包括单羧酸转运体关联）和CD147诱导mmp功能方面的作用。第五，CD147细胞质尾部将被用作探针，寻找与CD147功能相关的细胞内关键分子。第六，在Aims 2-5中定义和表征的关键突变体将在乳腺癌细胞系中表达，并在体外和体内原位小鼠模型中测试对肿瘤细胞的影响。我们对抗受体结合、MMP诱导、细胞粘附、乳酸利用和小窝蛋白/微域组织协调的新见解，应该为更好地理解cd147对肿瘤细胞侵袭行为的巨大影响提供一个综合框架。